17.41
-0.54(-3.01%)
Currency In USD
| Previous Close | 17.95 |
| Open | 18.11 |
| Day High | 18.17 |
| Day Low | 17.35 |
| 52-Week High | 19.18 |
| 52-Week Low | 4.45 |
| Volume | 874,688 |
| Average Volume | 1.13M |
| Market Cap | 955.23M |
| PE | -4.46 |
| EPS | -3.9 |
| Moving Average 50 Days | 14.93 |
| Moving Average 200 Days | 13.64 |
| Change | -0.54 |
If you invested $1000 in uniQure N.V. (QURE) 10 years ago, it would be worth $640.78 as of September 08, 2025 at a share price of $17.41. Whereas If you bought $1000 worth of uniQure N.V. (QURE) shares 5 years ago, it would be worth $434.82 as of September 08, 2025 at a share price of $17.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
GlobeNewswire Inc.
Sep 05, 2025 11:05 AM GMT
~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~ ~ All patients in first cohort discontinued enzyme replacement therapy ~ ~ Preliminary data show AMT-191 has a manageabl
uniQure to Announce Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Jul 22, 2025 11:05 AM GMT
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ETLEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients wit
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
GlobeNewswire Inc.
Jun 11, 2025 12:00 PM GMT
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapi